Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHX-001 in Sub-Optimally Responsive Major Depressive Disorder
NCT03721900Phase 1Unknown
- Sponsor
- Shenox Pharmaceuticals LLC
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SHX-001 in major depressive disorder (MDD) (3 arms), sponsored by Shenox Pharmaceuticals LLC. Primary endpoints: Pharmacokinetics of SHX-001 (Cmax) at 1 week, Pharmacokinetics of SHX-001 (Tmax) at 1 week and 1 more. Status: unknown.
02
Drugs
SHX-001
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03721900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721900.